To further investigate these findings, we analyzed the ROR2 expression in a large cohort of low-grade early-stage endometrial carcinomas (150 samples from CTNNB1 wild-type tumors and 15 from mutated counterparts). This evidence concerns the gene CTNNB1 and endometrial carcinoma.